Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Asker Healthcare Group AB (ASKER.ST)
Danderyd, SE
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.98% | -2.82% | +12.45% | +24.71% | -12.59% | -1.70% | -10.54% | -3.41% | -3.41% | -3.41% | -3.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+11.7% ★ Q1'26: +13.2% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+33.0% ★ Q1'26: +163.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+3.1% Q1'26: +7.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+7.3% Q1'26: +6.9% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+8.3% ★ Q1'26: +8.0% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-3.9% ★ Q1'26: +18.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×4.72× Q1'26: 2.74× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
16.79B
est: 16.88B (-0.6%)
|
18.99B
18.95B – 19.03B
+12.5% YoY
|
20.50B
19.54B – 21.31B
+7.9% YoY
|
22.09B
21.53B – 22.56B
+7.8% YoY
|
23.24B
22.65B – 23.74B
+5.2% YoY
|
23.29B
22.69B – 23.79B
+0.2% YoY
|
| EBITDA |
1.23B
est: 1.29B (-4.5%)
|
1.45B
1.45B – 1.45B
+12.5% YoY
|
1.56B
1.49B – 1.63B
+7.9% YoY
|
1.69B
1.64B – 1.72B
+7.8% YoY
|
1.77B
1.73B – 1.81B
+5.2% YoY
|
1.78B
1.73B – 1.82B
+0.2% YoY
|
| EBIT |
1.23B
est: 1.35B (-8.7%)
|
1.52B
1.51B – 1.52B
+12.5% YoY
|
1.64B
1.56B – 1.70B
+7.9% YoY
|
1.76B
1.72B – 1.80B
+7.8% YoY
|
1.86B
1.81B – 1.90B
+5.2% YoY
|
1.86B
1.81B – 1.90B
+0.2% YoY
|
| Net Income |
492.00M
est: 823.45M (-40.3%)
|
1.05B
915.69M – 1.26B
+28.1% YoY
|
1.21B
999.86M – 1.31B
+15.2% YoY
|
1.37B
1.32B – 1.41B
+12.6% YoY
|
1.60B
1.55B – 1.65B
+17.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
5.80B
est: 4.76B (+21.8%)
|
5.36B
5.34B – 5.37B
+12.5% YoY
|
5.78B
5.51B – 6.01B
+7.9% YoY
|
6.23B
6.07B – 6.36B
+7.8% YoY
|
6.55B
6.39B – 6.70B
+5.2% YoY
|
6.57B
6.40B – 6.71B
+0.2% YoY
|
| EPS |
1.25
est: 2.24 (-44.1%)
|
2.86
2.49 – 3.41
+28.1% YoY
|
3.30
2.72 – 3.56
+15.2% YoY
|
3.71
3.59 – 3.82
+12.6% YoY
|
4.35
4.21 – 4.47
+17.1% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares OMX Stockholm Capped UCITS ETF OM3X.DE | 0.20% | 429.2K | 0.10% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.11% | 189.9K | 0.41% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.10% | 3.46M | 0.30% |
| 4 | Schwab International Small-Cap Equity ETF SCHC | 0.07% | 3.89M | 0.06% |
| 5 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.06% | 526.6K | 0.23% |
| 6 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.06% | 526.3K | 0.23% |
| 7 | Avantis International Small Cap Equity ETF AVDS | 0.06% | 200.8K | 0.30% |
| 8 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.05% | 7.10M | 0.06% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.05% | 108.1K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.05% | 6.51M | 0.40% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emma Rheborg | Head of Communication | — | female |
| Jennie Espelund | General Counsel | — | female |
| Johan Falk | Chief Executive Officer | — | male |
| Kerstin Mjomark | Head of HR & ESG | — | female |
| Lovisa Hedin | Head of M&A | — | female |
| Mattias Jaran | Head of IT Integrity | — | male |
| Ola Nordh | Head of Mergers & Acquisitions | — | male |
| Sanna Norman | Head of ESG | — | female |
| Thomas Moss | Chief Financial Officer & Head of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASKER.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
